5 Micro-Cap Stocks to Buy According to Cathie Wood

Page 1 of 5

In this article, we discuss the 5 micro-cap stocks to buy according to Cathie Wood. If you want our detailed analysis of Cathie Wood’s investment philosophy and hedge fund performance, go directly to the 10 Micro-Cap Stocks to Buy According to Cathie Wood

5. Evogene Ltd. (NASDAQ:EVGN)

ARK Investment Management’s Stake Value: $10,653,000

Percentage of ARK Investment Management’s 13F Portfolio: 0.02%

Number of Hedge Fund Holders: 6

Market Capitalization: $84.387 million

Roth Capital analyst Brian Wright initiated coverage of Evogene Ltd. (NASDAQ:EVGN) on October 8 with a Buy rating and a $7 price target, citing the company’s robust pipeline of pre-clinical micro biome-based drug candidates in its biotech subsidiary and Evogene Ltd. (NASDAQ:EVGN) being on the cusp of commercialization of its first products in ag-biologics and cannabis.

A computational biology company engaged in product discovery and development in the life sciences industries like human health and agriculture, Evogene Ltd. (NASDAQ:EVGN) applies its technology platform, Computational Predictive Biology (CPB), leveraging big data and AI to guide the development of life sciences products by studying microbes, small molecules, and genetic elements.

Cathie Wood owns more than 4 million Evogene Ltd. (NASDAQ:EVGN) shares worth $10.65 million in the third quarter, representing 0.02% of her total 13F securities for Q3. 

A total of 6 hedge funds monitored by Insider Monkey at the end of September were long Evogene Ltd. (NASDAQ:EVGN), with stakes valued at $13 million. Jim Simons’ Renaissance Technologies increased its position in Evogene Ltd. (NASDAQ:EVGN) by 155% in the third quarter, holding a $700,000 stake in the company. 

On November 17, Evogene Ltd. (NASDAQ:EVGN) reported Q3 earnings, posting a loss per share of $0.19, missing estimates by $0.01. The quarterly revenue of $151,000 exceeded estimates by $39,000. 

Page 1 of 5